Keywords: Hikma, 2011 financial results
Hikma earnings down despite 25.6% revenue growth
Article | 14 March 2012
Fast-growing Jordan headquartered drugmaker Hikma Pharmaceuticals (LSE: HIK) delivered what it called a robust set of results for 2011, despite a ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Is failure to adopt business process management putting the pharma industry at risk?
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations
- Ignyta acquires Actagene Oncology and entry into cancer personalized medicine
